TY - JOUR
T1 - Roles of hypoxia response in retinal development and pathophysiology
AU - Kurihara, Toshihide
N1 - Funding Information:
This article was written based on the lecture that received the Kitasato Award presented at the 85th Kitasato Memorial Ceremony on June 10, 2016, at Kitasato Memorial Hall at the Keio University School of Medicine. I thank Drs. Kazuo Tsubota, Martin Friedlander, Hideyuki Okano, Susumu Ishida, Yoshiaki Kubota, and Yoko Ozawa for their mentorship in the original articles cited in this article. The author is supported by the Manpei Suzuki Diabetes Foundation, a JSPS Postdoctoral Fellowship, MEXT KAKENHI Grants, the Uehara Memorial Foundation, the Japanese Retinitis Pigmentosa Society, the Takeda Science Foundation, and the Keio University Medical Science Fund.
Publisher Copyright:
© 2017 by The Keio Journal of Medicine.
PY - 2018
Y1 - 2018
N2 - The hypoxia response is a fundamental phenomenon mainly regulated by hypoxia-inducible factors (HIFs). For more than a decade, we have investigated and revealed the roles of the hypoxia response in the development, physiology, and pathophysiology of the retina by generating and utilizing cell-typespecific conditional knockout mice. To investigate the functions of genes related to the hypoxia response in cells composing the retina, we generated various mouse lines that lack HIFs and/or related genes specifically in retinal neurons, astrocytes, myeloid cells, or retinal pigment epithelium cells. We found that these genes in the different types of retinal cells contribute in various ways to the homeostasis of ocular vascular and visual function. We hypothesized that the activation of HIFs is likely involved in the development and progress of retinal diseases, and we subsequently confirmed the pathological roles of HIFs in animal models of neovascular and atrophic ocular diseases. Currently, anti-vascular endothelial growth factor (anti-VEGF) therapy is a first-line treatment widely used for neovascular retinal diseases. However, alternative or additional targets are now required because several recent large-scale clinical trials and animal studies, including our own research, have indicated that VEGF antagonism may induce retinal vascular and neuronal degeneration. We have identified and confirmed a microRNA as a candidate for an alternative target against neovascular retinal diseases, and we are now working to establish a novel HIF inhibitor for clinical use based on the disease mechanism that we identified.
AB - The hypoxia response is a fundamental phenomenon mainly regulated by hypoxia-inducible factors (HIFs). For more than a decade, we have investigated and revealed the roles of the hypoxia response in the development, physiology, and pathophysiology of the retina by generating and utilizing cell-typespecific conditional knockout mice. To investigate the functions of genes related to the hypoxia response in cells composing the retina, we generated various mouse lines that lack HIFs and/or related genes specifically in retinal neurons, astrocytes, myeloid cells, or retinal pigment epithelium cells. We found that these genes in the different types of retinal cells contribute in various ways to the homeostasis of ocular vascular and visual function. We hypothesized that the activation of HIFs is likely involved in the development and progress of retinal diseases, and we subsequently confirmed the pathological roles of HIFs in animal models of neovascular and atrophic ocular diseases. Currently, anti-vascular endothelial growth factor (anti-VEGF) therapy is a first-line treatment widely used for neovascular retinal diseases. However, alternative or additional targets are now required because several recent large-scale clinical trials and animal studies, including our own research, have indicated that VEGF antagonism may induce retinal vascular and neuronal degeneration. We have identified and confirmed a microRNA as a candidate for an alternative target against neovascular retinal diseases, and we are now working to establish a novel HIF inhibitor for clinical use based on the disease mechanism that we identified.
KW - Hypoxia-inducible factor (HIF)
KW - Retina
KW - Vascular endothelial growth factor (VEGF)
KW - Von Hippel-Lindau protein (PVHL)
KW - microRNA
UR - http://www.scopus.com/inward/record.url?scp=85046442256&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85046442256&partnerID=8YFLogxK
U2 - 10.2302/kjm.2017-0002-IR
DO - 10.2302/kjm.2017-0002-IR
M3 - Review article
C2 - 28592747
AN - SCOPUS:85046442256
SN - 0022-9717
VL - 67
SP - 1
EP - 9
JO - Keio Journal of Medicine
JF - Keio Journal of Medicine
IS - 1
ER -